Sovaldi among several Japan approvals

Japan's Ministry of Health, Labor and Welfare (MHLW) approved Sovaldi sofosbuvir from Gilead Sciences Inc. (NASDAQ:GILD) and a basket of other drugs on Thursday.

In Japan, Gilead said Sovaldi is indicated in combination with ribavirin to treat cirrhotic and non-cirrhotic patients with HCV genotype 2 infection. Gilead said it will launch the drug as soon as possible, but did not respond to inquiries about its price. ...